Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 7/20 | 0.34 |
| ▸ | CDK8 | P49336 | 7/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103669 | 1.00 | CYP11B2 (0.40) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103681 | 0.98 | CYP11B2 (0.38) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103688 | 0.98 | CYP17A1 (0.40) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103634 | 0.97 | CYP17A1 (0.39) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103643 | 0.97 | CYP17A1 (0.39) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103676 | 0.97 | CYP17A1 (0.39) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103624 | 0.94 | PDK2 (0.40) | PDK2TNFMAPK10 | |
| SCHEMBL1102655 | 0.93 | CYP11B1 (0.39) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1102707 | 0.92 | CYP17A1 (0.41) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL1103678 | 0.92 | PDK2 (0.39) | PDK2TNFMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | CYP11B2 652/4885CYP11B1 836/4885CYP17A1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.